Drugmaker Lupin on Monday said it has received an Establishment Inspection Report (EIR) from the US health regulator for its manufacturing plant in Nagpur. The US Food and Drug Administration (USFDA) issues an EIR to a company when an inspection is satisfactorily closed.
The health regulator had inspected the company's Nagpur manufacturing facility between January 6 and January 10, 2020, Lupin Ltd said in a statement.
"We are very happy to have received the EIR for our Nagpur facility, our largest and most advanced oral solid dosage facility. We remain committed to enhancing compliance and quality standards across all our manufacturing sites," Lupin Managing Director Nilesh Gupta said.
Check out Lupin Ltd. stock here.
Check out Lupin Laboratories Ltd. stock here.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
